Biofer S.p.a.

Alessandro Lapini Sacchetti

Egidio Marchi

Dario Bosi

Patrizia Santi

Cristina Padula

Claudia Ori

Lisa Preti

Michele Autuori

The present invention relates to novel pyrido-imidazo rifamycins, characterized by a highly selective antibacterial activity and low absorption by oral route.

Pyrido-imidazo rifamycins

A new modus and a new regimen of administration of divalent iron relates to therapy of hyposideremia, at the same time reducing toxic side effects. New formulations containing divalent iron compounds are adapted to release iron for intrabuccal absorption, preferably by sublingual absorption, that achieve these objects.

Modus of administration of iron, and new formulations adapted for the said goal

New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceutical compositions adapted for this use. In particular, the invention provides a new complex between preferably trivalent iron and maltobionic acid that is characterized by a molecular weight Mw between 10,000 and 30,000 Da, by a polydispersity of 1.0-1.8 and by an iron content between 25% and 40% by weight.

Low molecular weight complexes between iron and maltobionic acid, use thereof for intramuscular or subcutaneous administration in the treatment of anemic states, and new pharmaceutical compositions adapted for these uses

Growing community of inventors

Modena, Italy

Alessandro Lapini Sacchetti